Innovative Collaborations MIMETAS has established strategic partnerships with global pharmaceutical companies like Roche and Astellas to develop human disease models for innovative therapies, presenting sales opportunities through collaborative projects and service offerings.
Award-Winning Recognition As the winner of prestigious awards like the Dutch Innovation Prize, MIMETAS' cutting-edge technology and industry leadership positions the company as a desirable partner for pharmaceutical companies seeking breakthrough solutions, creating sales opportunities based on industry recognition and credibility.
Expanded Product Line The launch of new products, such as ASC-derived Colon1 and Kidney2 Organoid tubules, enhances MIMETAS' offerings in disease modeling, providing sales opportunities to introduce these advanced solutions to pharmaceutical companies looking to enhance their drug development processes.
Experienced Leadership With the appointment of Dhaval Patel as Chair of the Board of Directors, MIMETAS strengthens its leadership team, presenting sales opportunities through leveraging the expertise and industry connections of seasoned professionals to drive collaborations and business growth.
Market Validation Through Funding MIMETAS' substantial revenue and funding position in the range of $10M to $50M indicates market viability and financial stability, making the company an attractive choice for pharmaceutical partners and investors, leading to potential sales opportunities based on financial health and growth potential.
1K
$100M$1B
93$10M$50M
22
143$10M$50M
14$10M
12$10MMIMETAS uses 8 technology products and services including Google Analytics, Google Font API, jQuery, and more. Explore MIMETAS's tech stack below.
| MIMETAS Email Formats | Percentage |
| F.Last@mimetas.com | 33% |
| First.Last@mimetas.com | 21% |
| First@mimetas.com | 13% |
| F.Last@mimetas.com | 33% |
Biotechnology ResearchOegstgeest, Netherlands51-200 Employees
We strive to contribute to groundbreaking therapies with our screenable, physiologically relevant 3D human disease models. By combining technological strengths and expertise, we establish strong drug development partnerships with and offer services to global pharmaceutical companies to develop innovative therapies to target untreatable diseases. For more information, visit: www.mimetas.com.
Company Overview
Media & News
Funding & FinancialsMIMETAS has raised a total of $3.5M of funding over 5 rounds. Their latest funding round was raised on Jan 01, 2019 in the amount of $3.5M.
MIMETAS's revenue is in the range of $10M$50M
Funding & FinancialsMIMETAS has raised a total of $3.5M of funding over 5 rounds. Their latest funding round was raised on Jan 01, 2019 in the amount of $3.5M.
MIMETAS's revenue is in the range of $10M$50M
1-888-653-2347 
support@leadiq.com